Network meta-analysis of 9 RCTs (3266 participants) in compensated MASH cirrhosis: efruxifermin was the only treatment significantly better than placebo for fibrosis regression; efruxifermin, semaglutide and semaglutide + cilofexor + firsocostat improved MASH resolution.
Meta-analysisn = 3,266
Souza et al. Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution